As Aurinia Pharmaceuticals Inc. marches ahead with the phase III trial testing what could become the first approved lupus nephritis (LN) therapy, company backers are watching with interest another, lesser known indication where the cyclosporine analogue voclosporin might also work: focal segmental glomerular sclerosis (FSGS), a glomerular disease that can cause nephrotic syndrome. A phase II experiment is slated to start next month. Both conditions involve high amounts of protein in the urine, or proteinuria. Read More
The regenerative medicine sector continues to thrive according to the first-quarter 2018 report released by the Alliance for Regenerative Medicine (ARM), the Washington-based organization that advocates and supports the global development of regenerative and advanced therapies. Coming off an approximate 9 percent year-over-year growth in the number of regenerative medicine companies around the world at the end of last year, ARM identified 861 regenerative medicine companies that are currently in operation, including those involved in gene and cell therapies and tissue engineering. Read More
